Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tivantinib

Daiichi Sankyo logo

Daiichi Sankyo offloads stake in India’s Sun Pharma

Japanese firm wants to shed its share of the generic Indian drugmaker

- PMLiVE

Survey reveals problems with lung cancer mutation testing

A quarter of patients surveyed not receiving EGFR testing prior to treatment

- PMLiVE

AstraZeneca and PatientsLikeMe team up on real-world data

Two groups hoping to harness the power of the patient forum network

- PMLiVE

Campaigns improve cancer symptom awareness, claims BJC

Has shown an increase in GP visits for possible cancer symptoms

- PMLiVE

Novartis and GSK complete oncology and vaccines swap

Follows Swiss company's decision to divest its BRAF and MEK inhibitors to Array BioPharma

- PMLiVE

Merck takes promotional responsibility for Erbitux in Japan

Currently co-promotes the drug withBristol-Myers Squibb

- PMLiVE

Takeda’s lung cancer drug motesanib flunks another trial

Drug was unable to extend progression-free survival in study of 400 patients

EISAI

Eisai given early approval for new oncology drug

Japanese firm’s thyroid cancer treatment Lenvimaset to be a blockbuster

- PMLiVE

Inventor turns bomb detector into cancer breathalyser

Clinical trials of Billy Boyle's device will be held in two NHS hospitals

- PMLiVE

AZ and University of Texas to collaborate on cancer research

Studies will aim to improve patient outcomes

- PMLiVE

Pfizer’s Ibrance wins early breast cancer approval in US

FDA’s decision come two months ahead of schedule

Roche - Basel

Roche’s PD-1 wins second FDA ‘breakthrough’ status

Will accelerate review of MPDL3280A in lung cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links